Johnson & Johnson (JNJ)vsWarby Parker Inc (WRBY)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
WRBY
Warby Parker Inc
$24.43
-2.55%
HEALTHCARE · Cap: $2.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10797% more annual revenue ($99.33B vs $911.61M). JNJ leads profitability with a 16.2% profit margin vs 0.8%. JNJ trades at a lower P/E of 38.8x. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
WRBY
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Margin of Safety
-6.1%
Fair Value
$20.73
Current Price
$24.43
$3.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
ROE of 0.4% — below average capital efficiency
0.8% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 389.0x leaves little room for execution misses. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.90 — expect wider price swings.
WRBY is growing revenue faster at 9.8% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 30/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is an innovative direct-to-consumer eyewear company that has redefined the eyewear shopping experience since its inception in 2010. With a successful blend of e-commerce and physical retail expansion, the company offers stylish and affordable prescription glasses and sunglasses, appealing to a broad demographic. Warby Parker is distinguished by its commitment to social responsibility, exemplified by its "Buy a Pair, Give a Pair" initiative, which underscores its dedication to making a positive impact. As the company leverages its strong brand reputation and effective marketing strategies, it is well-positioned for continued growth in the increasingly competitive eyewear sector, addressing evolving consumer preferences while enhancing its social mission.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?